Abstract
Metagenomic sequencing analysis has been implemented as an alternative approach for pathogen diagnosis in recent years, which is independent on cultivation and able to identify all potential antibiotic resistant genes. However, current metagenomic sequencing analysis methods have to deal with low amounts of prokaryotic DNA and high amounts of host DNA in clinical samples, which significantly decrease the overall microbial detection resolution. The recently released nanopore adaptive sampling (NAS) technology facilitates immediate mapping of individual nucleotides to a given reference as each molecule is sequenced. User-defined thresholds allow for the retention or rejection of specific molecules, informed by the real-time reference mapping results, as they are physically passing through a given sequencing nanopore. We developed a metagenomics workflow for ultra-sensitive diagnosis of bacterial pathogens and antibiotic resistance genes (ARGs) from clinic samples, which is based on the efficient selective ‘human host depletion’ NAS sequencing, real-time species identification and species-specific resistance gene prediction. Our method increased microbial sequence yield at least 8-fold in all 11 sequenced clinical Bronchoalveolar Lavage Fluid (BALF) samples (4.5h from sample to result), displayed 100% sensitivity and specificity for pathogen detection compared with cultivation method, and accurately detected antibiotic resistance genes at species level.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Key Research and Development Program of China (Grant No. 2021YFA1202500); the Guangdong Natural Science Foundation for Distinguished Young Scholar [2020B1515020003]; the Shenzhen Key Laboratory of Gene Regulation and Systems Biology, Southern University of Science and Technology [ZDSYS20200811144002008]; and Shenzhen Science and Technology Program KQTD20200909113758004; National Natural Science Foundation of China [42007216].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital) gave ethical approval for this work[Approval Number: KY-2020-032-01].
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† The authors wish it to be known that the first two authors should be regarded as Joint First Authors.
His research interests include ONT sequence and bioinformatics.
She majors in bioinformatics.
He majors in infection disease.
He majors in infection disease.
His research interests include pathogenic microbiology and bioinformatics.
Her research interests include environmental microbiology and bioinformatics.
Data Availability
All clinical sample sequence data (both Illumina and Nanopore) used in the present study has been deposited in the NCBI database under project ID PRJNA821338.
